Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.
about
Loss of Dnmt3a and Dnmt3b does not affect epidermal homeostasis but promotes squamous transformation through PPAR-γThe genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaAberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1FLT3 inhibitors: clinical potential in acute myeloid leukemia.Preleukemia: one name, many meanings.Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells.Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer.Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.Emergence of heterogeneity in acute leukemias.The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9.Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.Can exome scans be expected to be part of real-time decision-making in patients with haematological cancers?DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment.Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.Tracing the origins of relapse in acute myeloid leukaemia to stem cells.Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling.Mutational interactions define novel cancer subgroupsNuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives
P2860
Q33675655-7523B7F8-08D6-47CE-9160-10C897A6950CQ33796552-8EEAF2FE-A57D-4533-838A-EC664AF273B0Q34047994-C02B0959-C69A-4BEA-AEB5-21EA13BDCAF4Q34529131-F2642D88-16F0-4989-8766-B4175A1B6945Q37325612-DE9BC77A-BA74-40B1-AF56-7DA5C738D8C3Q37638749-80C1597F-0060-4766-8481-D96E9FE72596Q37683379-1D5318C5-653C-46D8-975A-0F1FB7ADB7D4Q37702556-1F215104-11C4-43B2-ACAA-2F094D9FCE13Q38374992-F4A6D496-9BA0-4C15-B8D3-F25A185791C8Q38755213-B190D67B-250B-4A50-A1C9-581C2A1E8BD9Q38800948-B11C1227-63B3-44BF-9F1F-494B40A2E443Q39176607-90F969BE-4B36-489A-B049-F56C293407ACQ39252132-4BBBB909-4DA2-4F16-8F50-50A9D9270FF3Q39298587-A38FD46D-E012-494A-8E6A-5428639ED293Q39460854-D3B321CE-C258-464E-91BB-51D7F9FA2FBFQ41550563-F6A62E13-926F-4F5C-81F4-59D8D5477C5FQ46406409-5F8B1AD9-6A76-418B-8407-D531D6681D30Q47936319-47EC632C-C6D3-48DA-8676-4D680E1D64CEQ48034587-8FEF20FF-D58A-46EE-B999-7CF17DC18CABQ48183562-163CFC47-772F-4F03-B7DC-1EEC516215A0Q48255315-C2692255-E3DE-4649-A1A5-3637093D8870Q48568744-DAD0ED32-F6A5-41B8-A4BD-69447271BDE5Q49722374-9CD3A39B-6D03-4B98-B743-458C8CE37C6CQ49787877-2305792E-27B8-4008-856C-ABD9EADE009EQ50097999-C95B3FFD-7280-4A35-919A-0BF7BC628169Q51426321-5B065BDC-D132-4122-A5AD-CDF3818292D3Q51838074-DCE200FF-BC9C-4C37-A7CC-84646F85B2C9Q54109032-8A490BAD-3568-4ABC-95AB-8C02D0F8A8D2Q55402884-71964A69-03FD-4501-A76D-8BB781E806FBQ57810947-97FE0C4A-F2E1-44FD-9426-EAF560644BFFQ58555302-7CECD0C6-286B-4301-ABD8-7A550A20E771
P2860
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Profiling of somatic mutations ...... -ITD at diagnosis and relapse.
@ast
Profiling of somatic mutations ...... -ITD at diagnosis and relapse.
@en
type
label
Profiling of somatic mutations ...... -ITD at diagnosis and relapse.
@ast
Profiling of somatic mutations ...... -ITD at diagnosis and relapse.
@en
prefLabel
Profiling of somatic mutations ...... -ITD at diagnosis and relapse.
@ast
Profiling of somatic mutations ...... -ITD at diagnosis and relapse.
@en
P2093
P2860
P50
P1433
P1476
Profiling of somatic mutations ...... -ITD at diagnosis and relapse.
@en
P2093
Abhishek Sampath
Allen Eng-Juh Yeoh
De-Chen Lin
Deepika Kanojia
H Phillip Koeffler
Hagop M Kantarjian
Henry Yang
Hiroki Yamaguchi
Hiroko Tanaka
Igor-Wolfgang Blau
P2860
P304
P356
10.1182/BLOOD-2015-05-646240
P407
P50
P577
2015-10-05T00:00:00Z